Why the CSL share price was a market-beater in August

The CSL Limited (ASX:CSL) share price was a market-beater again in August. Is it too late to invest?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price continued its market-beating form in August with another solid gain.

The biotherapeutics giant's shares finished the period with a gain of 5.2%, stretching their year to date return to almost 40%.

Why did the CSL share price charge higher in August?

Investors were buying the company's shares last month after it reported another strong full year result.

In FY 2019 CSL posted revenue of US$8,539 million and a net profit after tax of US$1,919 million, which was an 11% and 17% constant currency increase, respectively, on FY 2018's results. The latter was at the upper end of its guidance range of US$1,880 million to US$1,950 million, exactly as management had promised.

Once again it was CSL's Immunoglobulins sales which were the key driver of its growth. Immunoglobulins sales increased 16% on the prior corresponding period to US$3,543 million in FY 2019.

Supporting this growth was a 6% lift in Speciality sales and a 15% jump in Albumin sales, leading to the CSL Behring business reporting an 11% increase in total revenue to US$7,343 million during the 12 months.

The company's Seqirus influenza vaccine business also performed strongly in FY 2019. The Seqirus business posted a 12% increase in total revenue to US$1,196 million. This solid result was driven by a 19% increase in the sales of seasonal influenza vaccines.

Also catching the eye of investors was management's guidance for the year ahead. Despite the one-off financial headwind of transitioning to a new model of direct distribution in China, management expects solid profit growth in FY 2020.

It has provided guidance for net profit after tax in the range of approximately $2,050 million to $2,110 million in constant currency, which represents annual growth of approximately 7% to 10%.

Is it too late to invest?

Although I think its shares are arguably fully valued now, if you're looking for long-term investments then I would still be a buyer of its shares today. This is due to the quality of the company and its solid long-term growth potential thanks to its current portfolio and potentially lucrative product pipeline.

In addition to CSL, I think Cochlear Limited (ASX: COH) and ResMed Inc. (ASX: RMD) would be outstanding buy and hold options in the healthcare sector.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. and CSL Ltd. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords stock just rocketed 34% on strong earnings growth

Investors just sent this ASX All Ords stock surging 34%. Here’s what’s happening.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Gainers

Why Dimerix, Newmont, Regal Partners, and Titomic shares are storming higher

These shares are having a good finish to the week. Let's see why.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Share Gainers

Why Fortescue, Lynas, PEXA, and Regis Healthcare shares are charging higher

These shares are having a strong session on Thursday. But why?

Read more »

A young man talks tech on his phone while looking at a laptop. A financial graph is superimposed across the image.
Share Gainers

Why Capricorn Metals, Insignia, Perseus Mining, and Qoria shares are storming higher

These shares are having a strong session on Tuesday. But why?

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Share Gainers

Why Amaero, AMP, Block, and South32 shares are racing higher today

These shares are starting the week on a positive note. But why?

Read more »

Ten happy friends leaping in the air outdoors.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another momentous session for ASX shares this Friday.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Share Gainers

Why BHP, Catalyst Metals, Mesoblast, and Pilbara Minerals shares are shooting higher

These shares are ending the week with a bang. But why?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »